Q3 2026 OrthoPediatrics Corp. Earnings Conference Call - ORTHOPEDIATRICS CORP

Financial Performance:

• Third-quarter 2026 revenue reached a record $72.7 million, a 19% year-over-year increase from $61.2 million.
• Gross margin held steady at 74%, with total operating expenses of $58.2 million.
• Adjusted EBITDA hit a record $6.9 million (approx. 10% margin), compared to $6.2 million in the prior year period.
• Non-GAAP net loss per share narrowed to $0.25 from $0.50; GAAP net loss per share was $0.23 vs. $0.24.
• Free cash flow turned positive at $1.6 million for the quarter, a $5.0 million improvement over the prior year's $3.4 million usage.
• Cash position ended the quarter at $45 million (including restricted cash) with an additional $20 million available on the term loan.
• Set deployment decreased to $2.5 million from $4.1 million in the prior year quarter.
• Intangible asset impairment of $0.6 million was recorded related to trademark carrying values.

Guidance and Future Outlook:

• Full-year 2026 revenue guidance raised to $270–$273 million, representing 14–16% growth.
• Adjusted EBITDA guidance reiterated at approximately $25 million for the full year.
• Company expects to deploy approximately $10 million in sets in 2026.
• Forecasted to achieve free cash flow breakeven or better in 2026 and remain positive in 2027 and beyond.
• Management expects the "super cycle" of new product launches to drive significant growth starting in 2027, though early-stage products will not fully contribute to 2026 revenue.
• Long-term goal includes expanding OPSB clinic count beyond 60 and increasing territory coverage to reach 27 territories by end of 2027.

Business Segments and Product Lines:

• Trauma and Deformity: Generated $52.6 million revenue (+19%), driven by share gains, 3P Hip system (now in full commercial launch), and continued OPSB growth.
• Scoliosis: Reported $19.2 million revenue (+18%), supported by VertiGlide adoption and Response Fusion systems; 170 units placed this quarter.
• OPSB (Orthotic and Brace): grew >20% with strong momentum; added 3 new products (PD-HIP Rigid "HIPPO", Knee Tractor) and now operates 60+ clinics.
• International: Revenue of $14.8 million (+18%), led by EMEA growth in trauma, deformity, scoliosis, and bracing; LAT-SAM performance solid despite lower set sales timing.
• New Product Launches: 3P Hip (full launch), PNP Retrograde (limited launch), DF2 brace (high adoption), and Traxio Halo system (sold out initial units).
• Pipeline: Ellie (electromechanical growing implant) targeting first inpatient procedures in early 2027; Varaxis (next-gen fusion) and 3P Small/Mini expected to launch in 2027.

Market and Competitive Landscape:

• Management reports strong procedure volumes in pediatric orthopedics, contrasting with mixed commentary from other industry players.
• 3P Hip and VertiGlide have enabled shifts from simple pricing contracts to single-vendor or high dual-vendor contracts, targeting 50–80% market share in treated facilities.
• DF2 brace adoption is rapid, currently present in nearly 50% of U.S. children's hospitals, becoming the new gold standard for femur fracture care.
• International expansion in EMEA is accelerating due to EU MDR approvals for legacy scoliosis portfolios, a segment previously minimal for the company.

Risks and Challenges:

• Capital allocation requires balancing aggressive product launches (super cycle) with free cash flow constraints; set deployment remains a key lever.
• LAT-SAM region faces headwinds from restricted set sales in Brazil and accounts receivable management.
• Regulatory risks associated with the approval timeline for the Ellie device (IDE approval pending).
• Seasonality in Q4, historically impacted by set sales to Brazil and specific large unit sales (e.g., 70 units in Q3), necessitating conservative guidance.

Management Commentary and Tone:

• Tone is highly confident and optimistic, characterized by repeated references to an "outstanding quarter" and being "early" in a multi-year growth super cycle.
• Management emphasizes disciplined expense management, noting that the Q3 spike in S&M was due to distributor quota kicks and non-recurring items.
• David Bailey and Fred Height highlighted a strategic shift toward higher ASP products and capital efficiency, asserting that the super cycle will improve margins and free cash flow in the long term.
• Confidence in OPSB is high, with 34 new systems launched (now 60+ clinics) and demand exceeding internal forecasts.

Analyst Questions and Answers:

• EBITDA/Cash Flow Leverage: Management explained Q3 S&M expense was anomalous due to distributor kickers; clarified that Q4 should see improved margins and a return to historical seasonality.
• Super Cycle Profitability: Confirmed new products drive margin expansion via higher ASPs, improved contract leverage (pulling legacy usage), and capital-efficient inventory models (no consignment for many OPSB items).
• OPSB Territory Expansion: Confirmed the company is ahead of schedule with 60+ clinics; targets 27 territories by end of 2027, driven by greenfield and acquisition hires.
• Surgical Volume/Seasonality: Reiterated strong procedure volumes in Q3 and no anticipated headwinds for Q4 or 2027, despite external market volatility.
• International Growth: Clarified that international growth is currently driven by legacy product adoption post-MDR approvals; new super cycle products will enter international markets later.
• Contracting Strategy: Noted success in converting hospitals to exclusive or high-share vendor status to utilize existing shelf inventory without additional set deployment costs.
• OPSB Economics: Validated that unit economics for new clinics are on track, though greenfield sites incur upfront investment costs that dilute short-term margins.

Other Key Points:

• The company helped nearly 42,000 children this quarter, bringing cumulative impact to over 1.4 million kids.
• VertiGlide now has 125+ formally trained surgeons and is utilized in 40+ hospitals.
• Osseo partnership remains a U.S.-focused strategic asset with no immediate plans for international distribution.
• Traxio Halo Gravity Traction System is sold out of initial limited units, with production accelerated for 2027 full market release.
• Management noted that while 70-unit sales boosted Q3, they are not factoring them into future guidance to maintain a conservative outlook.